Announcement

Collapse
No announcement yet.

Possible opportunity

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • #16
    Originally posted by lunasicc42 View Post
    on the website provided it mentions that their parent company is Pharmicell, so me wonders if it's this: https://clinicaltrials.gov/ct2/show/...rmicell&rank=6
    Good pickup. In this link we see the mentioned doctors:
    are these a match for at least the two Kim's listed at http://www.hskclinic.com/eng/download/brochure.pdf shown below?
    Dr. Kim Hyeonsu, Executive Director
    Dr. Kim Deokgi, Director
    Dr. Lim Gangwon, Director
    Yes, Pharmicell is mentioned at 12s point by Dr. Kim Hyeonsu:

    Last edited by Pauly1; 09-10-2017, 11:37 AM.

    Comment


    • #17
      Originally posted by Pauly1 View Post
      Good pickup. In this link we see the mentioned doctors:


      are these a match for at least the two Kim's listed at http://www.hskclinic.com/eng/download/brochure.pdf shown below?


      Yes, Pharmicell is mentioned at 12s point by Dr. Kim Hyeonsu:

      I actually mean it when I say this: seems legit
      "That's not smog! It's SMUG!! " - randy marsh, southpark

      "what???? , you don't 'all' wear a poop sac?.... DAMNIT BONNIE, YOU LIED TO ME ABOUT THE POOP SAC!!!! "


      2010 SCINet Clinical Trial Support Squad Member
      Please join me and donate a dollar a day at http://justadollarplease.org and copy and paste this message to the bottom of your signature

      Comment


      • #18
        http://www.hskclinic.com/eng/download/brochure.pdf does tell us Dr.Kim Kyeonsu is CEO of Pharmicell and was involved with govt stem cell research.
        This is the real deal. If anybody is qualified to do stem cell injections it's this man. Here we see the commercial delivery of his years of stem cell research.
        Attached Files

        Comment


        • #19
          I don't think that the Dr. Kim of Dr. Kim's Stem Cells is the same Dr. Kim who co-authored the clinical trial article.
          The first initials don't match up.
          How is this treatment different from the aspiration and injection clinics in Mexico or Panama?
          Last edited by 2drwhofans; 09-10-2017, 02:54 PM.

          Comment


          • #20
            Contacted Dr. Kim on Facebook for a quote and overview of services. He wants US$60k, placing him on the premium end of the market for what is the most legit SCI stem cell therapy. Compare then Puhua & Wumedical in China want 25k and 30k respectively using neural stem cells. Panama is in the 35k range.

            Here's Dr. Kim reply on Facebook

            How are you? I’m Dr. Kim of stem cell clinic. Thank you for your concern.

            Briefly, Cellgram (c) is stem cell product that is culture expanded mesenchymal stem cell from autologous bone marrow. At 2011, it was approved in Korea FDA. Actually stem cell secrets many cytokines and growth factors those are repair damage tissue, suppress inflammations and regenerate. We have experienced spinal cord injury patients. ASIA A or penetrating injuries are not respond, but incomplete injury patients are good candidate. This stem cell product can resolve spasticity.

            After bone marrow aspiration, it needs 4 weeks for culture and manufacturing and then we can use. Bone marrow aspiration is very safe and painless procedure. In case of spinal cord injury, I inject stem cell via intrathecal space that is safe procedure.

            The price of Cellgram is 20,000 USD per unit. You need 3 times of stem cell injection consecutively.

            Sincerely yours From Dr. Hyunsoo Kim
            Last edited by Pauly1; 09-12-2017, 01:09 AM.

            Comment


            • #21
              Originally posted by Pauly1 View Post
              Contacted Dr. Kim on Facebook for a quote and overview of services. He wants US$60k, placing him on the premium end of the market for what is the most legit SCI stem cell therapy. Compare then Puhua & Wumedical in China want 25k and 30k respectively using neural stem cells. Panama is in the 35k range.

              Here's Dr. Kim reply on Facebook

              Has he done clinical trials?

              Comment


              • #22
                Jim, according to http://www.pharmicell.com/eng/pr/rep...l.html?seq=100, yes:

                Pharmicell proves the ‘effectiveness’ of stem cell therapy for spinal cord injury

                Stronger effects are shown with multiple dosing

                The promising research findings for patients with spinal cord injury (SCI) introduced in an international journal are drawing a big attention from the academic community.

                Pharmicell(005690) unveiled its findings on 29th that studies on the effects of Cellgram-SCI, stem cell therapeutics, to treat patients with spinal cord injury suggest that multiple dosing is much more effective than single dose use.

                Prof. Jeon Sang Yong of Seoul Asan Medical Center and his team have been using ‘Cellgram-SCI produced by Pharmicell to treat paralyzed patients on clinical trials and revealed their findings on the latest edition of the Journal of ‘Neurosurgery’, the official journal of the AANS (American Association of Neurological Surgeons).

                This is the second time that Jeon and his team presented treatment effects proven by clinical research using ‘Cellgram-SCI’ in the journal since 2012. In the previous clinical study, the Cellgram was injected into patients’ body three times but this time only one single dose was applied.

                Two rounds of clinical trials indicate that multiple dosing is way better than single dosing to improve the conditions of tetraplegia patients damaged by chronic spinal cord injury in the kinematic and neurological context,” said Jeon


                He more added, “Yet, MRI/DTI test results of some patients with improved conditions despite single dose of stem cell therapy injection show fiber continuity on the injured parts their spinal cord which was non-existent before the treatment, and that implies neural regeneration led by the stem cell therapy.”

                “Since regenerative ability of nerve cells is limited, stem cell-based therapies are desperately needed,” said Kim, Hyeon-Soo, head of Pharmicell. “These encouraging results from the trial will give a hope to patients suffering from incurable diseases including paralyzed patients damaged by spinal cord injury.”
                Last edited by Pauly1; 09-13-2017, 09:34 AM.

                Comment


                • #23
                  Originally posted by Jim View Post
                  Has he done clinical trials?
                  I'm not finding any publication with actual trial results yet.
                  http://spinalcordresearchandadvocacy.wordpress.com/

                  Comment


                  • #24
                    Grammy, from http://celltrials.info/2017/01/02/ce...year-review-2/ I found:

                    Big failures of clinical trials
                    .. Third, South Korean Phase 3 clinical trial, assessing efficacy if autologous bone marrow-derived mesenchymal stem cells in patients with chronic spinal cord injury was terminated in the middle due to futility. Only 2 patients out of 16 analyzed showed functional improvement. The study was supported by company Pharmicell.
                    Looked back to 2016 and found the linked article on webarchive, the abstract being:

                    Abstract

                    BACKGROUND:

                    In our previous report, 3 of 10 patients with spinal cord injury who were injected with autologous mesenchymal stem cells (MSCs) showed motor improvement in the upper extremities and in activities of daily living.

                    OBJECTIVE:
                    To report on the results of a phase III clinical trial of autologous MSCs therapy.
                    METHODS:
                    Patients were selected based on the following criteria: chronic American Spinal Injury Association B status patients who had more than 12 months of cervical injury, and no neurological changes during the recent 3 months of vigorous rehabilitation. We injected 1.6 ? 107 autologous MSCs into the intramedullary area at the injured level and 3.2 ? 107 autologous MSCs into the subdural space. Outcome data were collected over 6 months regarding neurological examination, magnetic resonance imaging with diffusion tensor imaging, and electrophysiological analyses.

                    RESULTS:
                    Among the 16 patients, only 2 showed improvement in neurological status (unilateral right C8 segment from grade 1 to grade 3 in 1 patient and bilateral C6 from grade 3 to grade 4 and unilateral right C8 from grade 0 to grade 1 in 1 patient). Both patients with neurological improvement showed the appearance of continuity in the spinal cord tract by diffusion tensor imaging. There were no adverse effects associated with MSCs injection.
                    CONCLUSION:

                    Single MSCs application to intramedullary and intradural space is safe, but has a very weak therapeutic effect compared with multiple MSCs injection. Further clinical trials to enhance the effect of MSCs injection are necessary.

                    The full text in the webarchive article goes into significant depth on how the MSC stem cells were cultivated and the method used for injection at the injury site.

                    We see they found that multiple injections of the MSC stem cells yield better results.

                    Comment


                    • #25
                      so is it essentially a NothingBurger with very modest results... I am interpreting mixed signals
                      "That's not smog! It's SMUG!! " - randy marsh, southpark

                      "what???? , you don't 'all' wear a poop sac?.... DAMNIT BONNIE, YOU LIED TO ME ABOUT THE POOP SAC!!!! "


                      2010 SCINet Clinical Trial Support Squad Member
                      Please join me and donate a dollar a day at http://justadollarplease.org and copy and paste this message to the bottom of your signature

                      Comment


                      • #26
                        Waiting is better

                        Comment


                        • #27
                          Originally posted by Jawaid View Post
                          Waiting is better
                          Yup. Found 2 recent articles citing Pharmicell's MSC cell as still under clinical trials and emerging tech.

                          Sep-2017: Translational Advances in the Management of Acute Spinal Cord Injury: What is New? What is Hot?
                          Mar-2017: Traumatic Spinal Cord Injury—Repair and Regeneration

                          Though if you have US$60k deep pockets and are OK with some improvements then Pharmicell has a history of SCI-related research and (likely) Dr.Kim is qualified to implant those MSC stem cells.
                          Last edited by Pauly1; 09-13-2017, 02:57 PM.

                          Comment


                          • #28
                            Originally posted by lunasicc42 View Post
                            so is it essentially a NothingBurger with very modest results... I am interpreting mixed signals

                            Big failures of clinical trials

                            Third, South Korean Phase 3 clinical trial, assessing efficacy if autologous bone marrow-derived mesenchymal stem cells in patients with chronic spinal cord injury was terminated in the middle due to futility. Only 2 patients out of 16 analyzed showed functional improvement. The study was supported by company Pharmicell.

                            (The phase 3 was terminated for lack of efficacy in chronic SCI). I wouldn't pay $60,000 for a therapy that couldn't cut the mustard in a trial. This is why clinical trials take place to begin with. It protects the patients from paying money for treatments that will probably only lighten their wallets as opposed to helping them. No is NO. The Signal: "terminated/failure"

                            Last edited by GRAMMY; 09-13-2017, 06:02 PM.
                            http://spinalcordresearchandadvocacy.wordpress.com/

                            Comment


                            • #29
                              Originally posted by GRAMMY View Post
                              Big failures of clinical trials

                              Third, South Korean Phase 3 clinical trial, assessing efficacy if autologous bone marrow-derived mesenchymal stem cells in patients with chronic spinal cord injury was terminated in the middle due to futility. Only 2 patients out of 16 analyzed showed functional improvement. The study was supported by company Pharmicell.

                              (The phase 3 was terminated for lack of efficacy in chronic SCI). I wouldn't pay $60,000 for a therapy that couldn't cut the mustard in a trial. This is why clinical trials take place to begin with. It protects the patients from paying money for treatments that will probably only lighten their wallets as opposed to helping them. No is NO.


                              Boo.
                              "That's not smog! It's SMUG!! " - randy marsh, southpark

                              "what???? , you don't 'all' wear a poop sac?.... DAMNIT BONNIE, YOU LIED TO ME ABOUT THE POOP SAC!!!! "


                              2010 SCINet Clinical Trial Support Squad Member
                              Please join me and donate a dollar a day at http://justadollarplease.org and copy and paste this message to the bottom of your signature

                              Comment


                              • #30
                                Grammy, they are reporting progress with different dosages:

                                2012: 3 of 10 patients with spinal cord injury who were injected with autologous mesenchymal stem cells (MSCs) showed motor improvement in the upper extremities and in activities of daily living.
                                dosage: 4 ? 10 cells were injected into the intradural space of 10 patients with American Spinal Injury Association class A or B injury caused by traumatic cervical SCI. After 4 and 8 weeks, an additional 5 ? 10 MSCs were injected into each patient through lumbar tapping.

                                2016: Single MSCs application to intramedullary and intradural space is safe, but has a very weak therapeutic effect compared with multiple MSCs injection. Further clinical trials to enhance the effect of MSCs injection are necessary.
                                Dosage: We injected 1.6 ? 107 autologous MSCs into the intramedullary area at the injured level and 3.2 ? 107 autologous MSCs into the subdural space.

                                2020: we wait for their progress report with higher dose.

                                Commercially Dr. Kim advised (and priced) 3 doses of the US$20k cellgram MSC stem cells which appears to take into consideration that a single dose was inadequate.

                                Comment

                                Working...
                                X